EATG » ViiV Healthcare submits NDA to FDA for the first long-acting, injectable treatment regimen for HIV

ViiV Healthcare submits NDA to FDA for the first long-acting, injectable treatment regimen for HIV

ViiV Healthcare submits New Drug Application (NDA) to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine for treatment of HIV

— If approved, cabotegravir and rilpivirine would be the first-ever long-acting, injectable treatment regimen for adults living with HIV.

Read the press release here.


 

Source:
ViiV Healthcare
News categories: HIV treatment, EMA/FDA